Study or Subgroup	SSRI Events	SSRI Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
Byerley et al. 1988	19	32	3	29	3.4%	5.74 [1.89, 17.40]
Dubé et al. 2009	1	62	1	138	0.7%	2.23 [0.14, 35.01]
Fabre et al. 1995	32	278	5	91	4.3%	2.09 [0.84, 5.22]
Fava et al. (A) 1998	19	55	1	9	1.5%	3.11 [0.47, 20.44]
Fava et al. (B) 1998	14	54	1	10	1.4%	2.59 [0.38, 17.57]
Feighner et al. 1999	36	521	6	129	4.7%	1.49 [0.64, 3.45]
Griebel et al. 2012 a	5	84	7	75	3.4%	0.64 [0.21, 1.92]
Griebel et al. 2012 b	13	80	3	77	3.0%	4.17 [1.24, 14.07]
LVM-MD-06	0	79	4	93	0.7%	0.13 [0.01, 2.39]
Lydiard et al. 1997	9	132	5	129	3.5%	1.76 [0.61, 5.11]
Mao et al (2015)	2	19	0	18	0.6%	4.75 [0.24, 92.65]
NCT00668525 (A)	18	322	2	109	2.3%	3.05 [0.72, 12.92]
NCT00668525 (B)	20	324	2	109	2.3%	3.36 [0.80, 14.16]
NCT01020799	1	50	1	99	0.7%	1.98 [0.13, 31.00]
NCT01473381	20	282	9	281	5.2%	2.21 [1.03, 4.78]
Nemeroff et al. 2007	10	104	5	102	3.7%	1.96 [0.69, 5.54]
Nierenberg et al (2007)	17	274	11	137	5.5%	0.77 [0.37, 1.60]
Rapaport (A) 2008	5	164	6	89	3.2%	0.45 [0.14, 1.44]
Rapaport (B) 2008	15	173	5	89	4.0%	1.54 [0.58, 4.11]
Ratti et al. 2011	11	120	3	120	2.8%	3.67 [1.05, 12.81]
Reimherr et al. 1990	13	149	15	150	5.6%	0.87 [0.43, 1.77]
Schatzberg 2006	10	100	5	96	3.7%	1.92 [0.68, 5.41]
Schneider 2003	19	371	5	376	4.0%	3.85 [1.45, 10.21]
SCT-MD 02 (A) 2002	15	125	2	64	2.3%	3.84 [0.91, 16.28]
SCT-MD 02 (B) 2002	5	123	1	63	1.2%	2.56 [0.31, 21.45]
SCT-MD-13	2	132	6	135	2.0%	0.34 [0.07, 1.66]
SCT-MD-27 (A)	10	136	3	67	2.8%	1.64 [0.47, 5.77]
SCT-MD-27 (B)	7	138	4	68	3.0%	0.86 [0.26, 2.84]
SND103288	8	172	8	160	4.1%	0.93 [0.36, 2.42]
Wang et al 2014	14	156	8	155	4.7%	1.74 [0.75, 4.03]
WELL AK130926	28	149	7	137	5.0%	3.68 [1.66, 8.15]
WELL AK130927	11	138	9	141	4.7%	1.25 [0.53, 2.92]
Total (95% CI)		**5098**		**3545**	**100.0%**	**1.69 [1.32, 2.17]**
Total events	409		153			

Heterogeneity: Tau² = 0.15; Chi² = 45.74, df = 31 (P = 0.04); I² = 32%

Test for overall effect: Z = 4.19 (P < 0.0001)